# US 2022/0044760 A9 · Gene Expression Profile Algorithm for Calculating a Recurrence Score for a Patient with Kidney Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0044760 A9
- Document ID: US20220044760A9
- Status: Published application
- Kind: A9
- Application number: 17/086,850
- Filed: 2020-11-02
- Published: 2022-02-10
- Earliest claimed: 2013-05-30
- Assignees: Genomic Health, Inc.
- Applicants: Genomic Health, Inc.
- Inventors: Steven SHAK; George Andrew WATSON; Michael R. CRAGER; Tara MADDALA; Margarita LOPATIN; Audrey GODDARD; Dejan KNEZEVIC; Christer SVEDMAN
- Web page: https://patentgrep.com/patent/US20220044760A9

## CPC

- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16C 99/00: Subject matter not provided for in other groups of this subclass
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16Z 99/00: Subject matter not provided for in other main groups of this subclass
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16Z: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR

## Abstract

The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method for obtaining a quantitative score for a patient with kidney cancer, comprising:
measuring a level of RNA transcripts in a tumor sample obtained from the patient from a set of genes, the set of genes consisting of: APOLD1, EDNRB, NOS3, PPAP2B, EIF4EBP1, LMNB1, TUBB2A, CCL5, CEACAM1, CX3CL1, and IL-6 and at least one reference gene;
normalizing the level of the RNA transcripts of APOLD1, EDNRB, NOS3, PPAP2B, EIF4EBP1, LMNB1, TUBB2A, CCL5, CEACAM1, CX3CL1, and IL-6 against a level of the RNA transcript of the at least one reference gene to provide a normalized level of the RNA transcripts of APOLD1, EDNRB, NOS3, PPAP2B, EIF4EBP1, LMNB1, TUBB2A, CCL5 , CEACAM1, CX3CL1, and IL-6; and
calculating a quantitative score result based on the normalized RNA transcript levels of CCL5, CEACAM1, and CXCL3, wherein the quantitative score is calculated as: (0.5CCL5+cEACAM1+CX3CL1)/3, where the gene name represents the normalized RNA transcript level of the named gene.

### Claim 22 (depends on 21)

The method of claim 21, wherein the kidney cancer is renal cell carcinoma (RCC).

### Claim 23 (depends on 21)

The method of claim 21, wherein the kidney cancer is clear cell renal cell carcinoma (ccRCC).

### Claim 24 (depends on 21)

The method of claim 21, wherein the tumor sample is obtained from a biopsy.

### Claim 25 (depends on 21)

The method of claim 21, wherein the tumor sample is paraffin-embedded and fixed.

### Claim 26 (depends on 21)

The method of claim 21, further comprising generating a report comprising the quantitative score.

### Claim 27 (depends on 21)

The method of claim 21, further comprising predicting a likelihood of recurrence of kidney cancer based on the quantitative score, wherein the quantitative score negatively correlates with risk of recurrence of kidney cancer.

### Claim 28 (depends on 21)

The method of claim 21, further comprising classifying the patient's risk of recurrence of kidney cancer based on the quantitative score by comparing the quantitative score to a quantitative score associated with average risk of recurrence for kidney cancer patients.

### Claim 29 (depends on 28)

The method of claim 28, wherein an increase in the quantitative score correlates with reduced risk of recurrence.

### Claim 30

A method for obtaining a quantitative score for a patient with kidney cancer, comprising:
measuring a level of RNA transcripts in a tumor sample obtained from the patient from a set of up to 11 genes, the set of genes comprising CCL5, CEACAM1, and CX3CL1 and at least one reference gene;
normalizing the level of the RNA transcripts of CCL5, CEACAM1, and CX3CL1 against a level of the RNA transcript of the at least one reference gene to provide a normalized level of the RNA transcripts of CCL5, CEACAM1, and CX3CL1; and
calculating a quantitative score result based on the normalized RNA transcript levels of CCL5, CEACAM1, and CXCL3, wherein the quantitative score is calculated as: (0.5CCL5+CEACAM1+CX3CL1)/3, where the gene name represents the normalized RNA transcript level of the named gene.

### Claim 31 (depends on 30)

The method of claim 30, wherein the kidney cancer is renal cell carcinoma (RCC).

### Claim 32 (depends on 30)

The method of claim 30, wherein the kidney cancer is clear cell renal cell carcinoma (ccRCC).

### Claim 33 (depends on 30)

The method of claim 30, wherein the tumor sample is obtained from a biopsy.

### Claim 34 (depends on 30)

The method of claim 30, wherein the tumor sample is paraffin-embedded and fixed.

### Claim 35 (depends on 30)

The method of claim 30, further comprising generating a report comprising the quantitative score.

### Claim 36 (depends on 30)

The method of claim 30, wherein the set of up to 11 genes further comprises at least one of APOLD1, EDNRB, NOS3, PPAP2B, EIF4EBP1, LMNB1, TUBB2A, and IL-6.

### Claim 37 (depends on 30)

The method of claim 30, further comprising predicting a likelihood of recurrence of kidney cancer based on the quantitative score, wherein the quantitative score negatively correlates with risk of recurrence of kidney cancer.

### Claim 38 (depends on 30)

The method of claim 30, further comprising classifying the patient's risk of recurrence of kidney cancer based on the quantitative score by comparing the quantitative score to a quantitative score associated with average risk of recurrence for kidney cancer patients.

### Claim 39 (depends on 38)

The method of claim 38, wherein an increase in the quantitative score correlates with reduced risk of recurrence.
